Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials
AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion acquisition of Cerevel Therapeutics. In Phase 2 studies ...
Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...
The centerpiece drug of AbbVie’s $9 billion acquisition of Cerevel Therapeutics has failed in two Phase II clinical ...
The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.
A trial drug has kept Desiree Dufour's breast cancer at bay — and now, the medication has been approved by the FDA. She has ...
Streamlining processes like trial site selection and FDA documentation can make a meaningful difference in development ...
A review of published psychiatric drug trials shows that successful outcomes are more often published, and unsuccessful ...
The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback